Lansoprazole Tablet, Orally Disintegrating
Product Images NDC 68382-772

5 FDA label images from Zydus Pharmaceuticals Usa Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 68382-772). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lansoprazole Delayed-release Orally Disintegrating Tablets (3de4f129 Dc87 48e1 B934 B2a038df8cf7 01)

Lansoprazole Delayed-release Orally Disintegrating Tablets (3de4f129 Dc87 48e1 B934 B2a038df8cf7 01)
Chemical structure of lansoprazole, depicting its molecular arrangement including a benzimidazole ring system, sulfinyl group, and substituted pyridine ring with trifluoromethoxy group.*
FDA Label Image

Lansoprazole Delayed-release Orally Disintegrating Tablets (3de4f129 Dc87 48e1 B934 B2a038df8cf7 02)

Lansoprazole Delayed-release Orally Disintegrating Tablets (3de4f129 Dc87 48e1 B934 B2a038df8cf7 02)
A line graph showing the mean severity of day heartburn plotted against days from the start of treatment for a placebo group and two Lansoprazole dosage groups (15 mg and 30 mg orally disintegrating tablets). The graph compares heartburn severity trends over approximately 60 days, illustrating treatment effects over time.*
FDA Label Image

Lansoprazole Delayed-release Orally Disintegrating Tablets (3de4f129 Dc87 48e1 B934 B2a038df8cf7 03)

Lansoprazole Delayed-release Orally Disintegrating Tablets (3de4f129 Dc87 48e1 B934 B2a038df8cf7 03)
A line graph depicting the mean severity of night heartburn over 60 days from the start of treatment. It compares three groups: placebo, lansoprazole 15 mg orally disintegrating, and lansoprazole 30 mg orally disintegrating. Both lansoprazole groups show a marked and sustained reduction in severity compared to placebo throughout the treatment period.*
FDA Label Image

Lansoprazole Delayed-release Orally Disintegrating Tablets, 15 mg (3de4f129 Dc87 48e1 B934 B2a038df8cf7 04)

Lansoprazole Delayed-release Orally Disintegrating Tablets, 15 mg (3de4f129 Dc87 48e1 B934 B2a038df8cf7 04)
Packaging label for Lansoprazole Delayed-Release Orally Disintegrating Tablets 15 mg by Zydus Pharmaceuticals USA Inc. The label indicates 100 tablets in a 10 x 10 unit-dose package, Rx only. It includes directions to pharmacists to dispense the Medication Guide separately and states the package is not child-resistant. The label also provides storage instructions and patient administration guidance.*
FDA Label Image

Lansoprazole Delayed-release Orally Disintegrating Tablets, 30 mg (3de4f129 Dc87 48e1 B934 B2a038df8cf7 05)

Lansoprazole Delayed-release Orally Disintegrating Tablets, 30 mg (3de4f129 Dc87 48e1 B934 B2a038df8cf7 05)
Packaging label for Lansoprazole Delayed-Release Orally Disintegrating Tablets, 30 mg strength. The label shows a 100-tablet count (10 x 10 unit-dose) with instructions and warnings. It is marked Rx only and distributed by Zydus Pharmaceuticals USA Inc. The label includes storage instructions and patient directions for use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.